Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy

This is an interventional treatment trial for Non-proliferative Diabetic Retinopathy focused on measuring diabetic retinopathy, diabetic macular edema, Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy Read More

Inclusion Criteria

• Adults ≥ 18 years;
• Diabetes mellitus (type 1, type 2 or other forms);
• Females who are not a woman of childbearing potential (WOCBP) or who agree to use contraception;
• At least one eye with moderately severe to severe NPDR (DRSS levels 47 or 53);
• Patients with diabetic macular edema (DME) may be eligible if they meet protocol specified eligibility criteria;
• Best corrected visual acuity (BCVA) early treatment of diabetes retinopathy study (ETDRS) letter score at screening ≥69 letters (approximate Snellen equivalent of 20/40 or better) in the study eye without CI-DME, or ≥75 letters when CI-DME is present (approximate Snellen equivalent 20/32 or better);
• Anti-vascular endothelial growth factor (VEGF) or any laser treatment is not required nor anticipated in either eye for least 6 months.

Exclusion Criteria:

• Body mass index > 40 kg/m2
• Uncontrolled diabetes mellitus such as hemoglobin A1c (HbA1C) > 10% or patients who are not currently treated for their diabetes;
• Uncontrolled hypertension defined as systolic > 160mmHg or diastolic > 100 mmHg (despite hypertensive medication);
• Proliferative Diabetes Retinopathy (PDR) in the study eye;
• Evidence of retinal neovascularization
• Any previous treatment with focal or grid laser photocoagulation or Pan-Retinal Photocoagulation (PRP);
• History of previously treated DME with fluocinolone acetonide implant (Iluvien®) injection in the study eye
• Visual acuity loss due to an ocular condition that would not improve from resolution of DME (i.e., foveal atrophy, pigment abnormalities, dense subfoveal hard exudates, nonretinal condition);
• History of vitreoretinal surgery;
• Intraocular surgery in the study eye within 4 months of randomization or anticipated over the course of the study;
• Uncontrolled glaucoma (e.g. visual field loss or defined as (IOP) ≥ 25 mmHg despite treatment with anti-glaucoma medication);
• Evidence of active infectious blepharitis, keratitis, scleritis, or conjunctivitis in either eye /any intraocular inflammation or infection in either eye within 4 months prior to randomization.